Posted by Diabetes South Texas Staff
News
Friday, November 29th, 2013
Diabetes Care: November 6, 2013
OBJECTIVE To evaluate the association between recurrent subthreshold depressive episodes and functioning in a prospective community sample of people with type 2 diabetes.
RESEARCH DESIGN AND METHODS A prospective community study in Quebec, Canada, was carried out between 2008 and 2013 (n=1064). Five yearly follow-up assessments (telephone interviews) were conducted. Baseline and the first three follow-up assessments were used to identify recurrent subthreshold depressive episodes (PHQ-9). Functioning (WHODAS-II) and health related quality of life (CDC unhealthy days) at four and five years follow up assessment were the outcome measure Read More
Posted by Diabetes South Texas Staff
Minority Diabetes Reports
Wednesday, November 20th, 2013
Aims/hypothesis
The aim of the study was to compare longitudinal changes in insulin sensitivity (SI) and beta cell function between women with and without a history of gestational diabetes mellitus (GDM).
Methods
The prospective follow-up cohort included 235 parous non-diabetic Mexican–American women, 93 with and 142 without a history of GDM. The participants underwent dual-energy x-ray absorptiometry, OGTTs and IVGTTs at baseline and at a median of 4.1 years follow-up. The baseline values and rates of change of metabolic measures were compared between groups. Read More
Posted by Diabetes South Texas Staff
Minority Diabetes Reports
Wednesday, November 20th, 2013
Diabetes Care: November 19, 2013
OBJECTIVE To assess racial differences in diabetes processes and intermediate outcomes of care in an internal medicine, patient-centered medical home (PCMH) group practice.
RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study of 1,457 adults with diabetes receiving care from 89 medical providers within a PCMH-designated, academic practice between July 1, 2009 and July 31, 2010. We used mixed-models to assess independent associations between patient race (non-Hispanic white or black) and 1) receipt of processes of care (A1C and LDL testing, foot and retinal examination, and influenza and pneumococcal vaccination) and 2) achievement of intermediate outcomes (LDL<100mg/dL, BP<140/90mmHg, A1C<7.0% [<53mmol/mol] and A1C>9.0% [>75mmol/mol]), controlling for sociodemographic factors, health status, treatment intensity and clinical continuity. Read More
Posted by Diabetes South Texas Staff
Minority Diabetes Reports
Wednesday, November 20th, 2013
American Journal of Public Health: Apr 24, 2013
Objectives. We sought to determine the role of neighborhood poverty and racial composition on race disparities in diabetes prevalence.
Methods. We used data from the 1999–2004 National Health and Nutrition Examination Survey and 2000 US Census to estimate the impact of individual race and poverty and neighborhood racial composition and poverty concentration on the odds of having diabetes.
Results. We found a race–poverty–place gradient for diabetes prevalence for Blacks and poor Whites. The odds of having diabetes were higher for Blacks than for Whites. Individual poverty increased the odds of having diabetes for both Whites and Blacks. Living in a poor neighborhood increased the odds of having diabetes for Blacks and poor Whites. Read More
Posted by Diabetes South Texas Staff
Minority Diabetes Reports
Wednesday, November 20th, 2013
Diabetes Spectrum: November 2013
Purpose. The purpose of this study was to examine Chinese Americans’ beliefs regarding professional Chinese medicine (CM) in diabetes management. Previous research showed substantial variations in Chinese Americans’ beliefs about the role of professional CM, such as acupuncture and herbal medicine, in diabetes management. To provide culturally sensitive care, health care providers (HCPs) need a nuanced understanding of patients’ beliefs about professional CM.
Methods. An interpretive phenomenological study was conducted. The sample included 20 informant couples (40 paired individuals) who were Chinese-American immigrants living with type 2 diabetes. Nineteen additional individuals were enrolled as respondents for member-checking. Semi-structured interviews were conducted in couple, group, and individual formats with informants and in groups only with respondents. Interviews were recorded, translated, transcribed, and coded for narrative and thematic analyses. Respondent responses validated informant findings. Read More
Posted by Diabetes South Texas Staff
Minority Diabetes Reports
Wednesday, November 20th, 2013
Ndep: 10/23
“Diabetes is a major threat to our American Indian and Alaska Native communities,” says Charlene Avery, M.D., chair of the American Indian and Alaska Native Work Group for the National Diabetes Education Program. “But it doesn’t have to be. As a community, we have the power to change this by taking a few small steps to prevent type 2 diabetes – for ourselves and generations to come.” Read more
Posted by Diabetes South Texas Staff
Clinical Trial News
Wednesday, November 20th, 2013
Springer: December 2013
Aims/hypothesis
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being treated with background metformin.
Methods
This randomised, double-blind, four-arm, parallel-group, Phase 3 study was conducted at 169 centres in 22 countries between April 2010 and August 2012. Participants (N = 1,284) with type 2 diabetes aged ≥18 and ≤80 years who had inadequate glycaemic control (HbA1c ≥7.0% [53 mmol/mol] and ≤10.5% [91 mmol/mol]) on metformin therapy received canagliflozin 100 mg or 300 mg, sitagliptin 100 mg, or placebo (n = 368, 367, 366, 183, respectively) for a 26 week, placebo- and active-controlled period followed by a 26 week, active-controlled period (placebo group switched to sitagliptin [placebo/sitagliptin]) and were included in the modified intent-to-treat analysis set. Randomisation was performed using a computer-generated schedule; participants, study centres and the sponsor were blinded to group assignment. The primary endpoint was change from baseline in HbA1c at week 26; secondary endpoints included changes in HbA1c (week 52) and fasting plasma glucose (FPG), body weight, and systolic blood pressure (BP; weeks 26 and 52). Adverse events (AEs) were recorded throughout the study. Read More
